Hohimer Wealth Management LLC Buys Shares of 55,824 Zoetis Inc. $ZTS

Hohimer Wealth Management LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 55,824 shares of the company’s stock, valued at approximately $4,012,000.

Several other institutional investors and hedge funds also recently modified their holdings of ZTS. Vanguard Group Inc. increased its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP lifted its stake in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares in the last quarter. State Street Corp grew its holdings in Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after buying an additional 189,235 shares during the last quarter. Finally, Norges Bank purchased a new position in Zoetis during the fourth quarter worth $734,425,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.9%

Shares of ZTS opened at $73.64 on Friday. The stock has a fifty day moving average of $76.30 and a two-hundred day moving average of $99.01. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. Zoetis Inc. has a fifty-two week low of $71.45 and a fifty-two week high of $160.48.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s dividend payout ratio is 34.93%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ZTS shares. Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. TD Cowen decreased their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Citigroup reduced their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.